Invasive Fungal Infections Clinical Trial
Official title:
Surveillance for Invasive Fungal Infections in Selected Hospitals in Dhaka City, Bangladesh
This will be an exploratory descriptive study designed to conduct surveillance for the identification of invasive fungal pathogens among hospitalized patients in Bangladesh at two tertiary care acute-level hospitals. including the Dhaka Medical College Hospital, the Dhaka Hospital of icddr,b, and the National Institute of Cancer Research Hospital (NICRH). Respiratory samples, blood, urine, cerebrospinal fluid, surgical wound infection swabs, and other samples including biopsy tissue specimens will be obtained at intensive care units, general medicine and surgery wards, post-operative care, etc. The collected specimens will be sent to the clinical microbiology laboratories of the surveillance hospitals or to the pathology laboratory (biopsy tissue specimens) to test for Aspergillus, Histoplasms, Candida, Pneumocystis, Cryptococcus, and Mucormycetes. The lab. methods will include microscopy, staining, culture, and biochemical tests mainly and if feasible then some specimens may undergo molecular or immunological methods.
1. Burden: Over 300 million people worldwide are infected with a deadly fungal infection, with 25 million at high risk of death or blindness. Population and disease demographics are used to calculate the worldwide burden of fungal diseases (age, gender, HIV infection, asthma, etc). Given the growing number of immunocompromised individuals especially among hospitalized patients who are at increased risk for invasive fungal infections, fungal illnesses require more attention than ever before. The importance of fungal diseases contributing to worldwide morbidity and mortality is emphasized. To assess the burden of these diseases more precisely, long-term, sustainable monitoring systems for fungal diseases, as well as better noninvasive and reliable diagnostic methods, are required. Even though most deaths from fungal illnesses are preventable, they are still a neglected topic by public health authorities. Other health issues, such as asthma, AIDS, cancer, organ transplantation, and corticosteroid therapy, can result in serious fungal infections. Antifungal therapy can be started right away if a correct diagnosis is made early. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. 2. Knowledge gap: Currently, there is no ongoing national surveillance system to detect invasive fungal pathogens or serious health threats. Hence, there is inadequate data on the burden, types, and diversity of fungal species in particular among hospitalized patients in Bangladesh. Some noteworthy issues affecting the proper diagnosis of invasive fungal pathogens in Bangladesh are an inadequate number of trained laboratory personnel to diagnose fungal diseases, only a few healthcare facilities performing fungal culture, insufficient awareness about severe fungal infections, lack of prioritization for fungal disease surveillance in healthcare delivery, lack of understanding about utilization of surveillance data to guide diagnosis and treatment, lack of antifungal drug stewardship and diagnostic stewardship and significant logistical challenges to ensure adequate biosecurity for diagnosis of and prevention against severe fungal infections. Relevance: Investigators need to take the necessary steps that will gradually lead to the establishment of a national surveillance system for invasive fungal pathogens, increase the generation of country-representative fungal surveillance data, improve surveillance data usage and reporting, and enhance IPC activities in Bangladesh. Objectives: To identify hospitalized patients infected with invasive fungal pathogens. Description of the research project: Methods: This will be an exploratory descriptive study designed to conduct surveillance for the identification of invasive fungal pathogens among hospitalized patients in Bangladesh at two tertiary care acute-level hospitals. The primary outcomes to be measured in this study: The proportion of laboratory-identified invasive fungal pathogens among hospitalized patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05749380 -
Pharmacokinetics and Safety of AmBisome and DKF-5122
|
Phase 1 | |
Not yet recruiting |
NCT02527928 -
Cost-Effectiveness of Amphotericin B
|
N/A | |
Completed |
NCT02851680 -
Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia.
|
N/A | |
Completed |
NCT03572049 -
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
|
Phase 2/Phase 3 | |
Suspended |
NCT05534529 -
Rezafungin Paediatric PK Study in Paediatric Subjects From Birth to <18 Years of Age
|
Phase 1 | |
Completed |
NCT04024995 -
Revision of Antifungal Strategies Definitions for Invasive Fungal Infections in Hematological Malignancies
|
||
Completed |
NCT00745992 -
Voriconazole Blood Level and Liver Metabolizing Enzyme in Taiwanese Patients
|
||
Completed |
NCT06413056 -
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
|
Phase 4 | |
Recruiting |
NCT05130723 -
Pharmacokinetics of Fluconazole in Children (2-18 Years)
|
||
Recruiting |
NCT04157465 -
Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients
|
N/A | |
Completed |
NCT04122560 -
Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration
|
Phase 4 | |
Completed |
NCT03262584 -
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
|
||
Completed |
NCT02678598 -
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
|
N/A | |
Completed |
NCT05491733 -
A Bioequivalence Study of APX001 High-load and Low-load Tablets
|
Phase 1 | |
Not yet recruiting |
NCT06220370 -
PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised.
|
||
Completed |
NCT04777058 -
Pharmacokinetics of Isavuconazole in Patients in the Intensive Care Unit
|
||
Recruiting |
NCT03583164 -
Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options
|
Phase 2 | |
Completed |
NCT03174457 -
Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study
|
||
Completed |
NCT00750737 -
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
|
Phase 3 | |
Not yet recruiting |
NCT06346951 -
Survey on the Current Status of IFD Diagnosis and Treatment by Intensive Care Physicians in Sichuan Province (IFS)
|